Oculis Upsized Loan Facility to Access up to CHF 100 million

Core Viewpoint - Oculis Holding AG has amended its loan facility with BlackRock, increasing its borrowing capacity to CHF 75 million, potentially up to CHF 100 million, providing significant financial flexibility as the company advances its clinical pipeline and prepares for key regulatory milestones [1][2][3][4]. Financial Agreement - The Amended Loan Agreement replaces a previous loan agreement from May 29, 2024, and includes three tranches of CHF 25 million each, with an additional loan of up to CHF 25 million available under mutually agreed terms [2]. - No amounts were drawn at the signing of the agreement, indicating that the company is maintaining its current cash reserves while securing additional funding [2]. Clinical Development and Milestones - The additional capital will support Oculis in achieving key milestones, including regulatory discussions with the FDA for three indications of Privosegtor (OCS-05) in the second half of 2025, and the initiation of Phase 2/3 trials for Licaminlimab (OCS-02) and Privosegtor (OCS-05) in 2H 2025 and 1H 2026, respectively [3]. - The company anticipates topline results from the OCS-01 Phase 3 DIAMOND trials in Q2 2026, with a potential NDA filing in 2H 2026 if results are positive [3]. Company Overview - Oculis is a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases, with a late-stage clinical pipeline that includes three core product candidates: OCS-01, Privosegtor (OCS-05), and Licaminlimab (OCS-02) [5]. - The company is headquartered in Switzerland and operates in the U.S. and Iceland, led by an experienced management team supported by international healthcare investors [5].